Protagen’s NavigAID array enables differential diagnoses and the classification of patient subgroups for better disease activity assessment and improved response prediction; all essential factors for the development of stratified therapies with the best possible chance of success.
Discover our pipeline of novel diagnostic tests from discovery and development to market-ready, CE-approved products across a range of autoimmune indications with unmet diagnostic and therapeutic needs.
Protagen applies its proprietary, automated screening platform technology (SeroTag™) for the detection of autoantibody signatures in patient serum to identify novel, proprietary, disease-specific biomarkers and support CDx development.
Protagen has focused on the identification of novel, proprietary biomarkers for SSC the first of which, BICD2, is now available as a CE-Mark assay and adds to our IVD portfolio of SCL70 and CENP-B, two standard markers used in the diagnosis of SSc.
Protagen is the leading specialist in the development of novel in-vitro diagnostic (IVD) tests, patient stratification tools and companion diagnostics (CDx) in the fields of immuno-oncology and autoimmune diseases. With a best-in-class IP portfolio, the company combines its extensive expertise in autoantigen and autoantibody profiling with proprietary technology platforms to detect disease-relevant biomarkers, identify novel therapeutic targets and develop new diagnostic tools.
Autoimmune Diagnostic Assays
Protagen's unique autoantibody screening technologies and biological repositories support the identification of novel, exclusive, disease-specific biomarkers for the development of new IVD assays. Focusing on a number of diseases with an unmet need, Protagen’s aim is to augment current tools to improve the diagnosis and management of diseases such as RA, SSc, and SLE. New tests will allow clinicians and researchers to better differentiate between autoimmune diseases and recognize specific disease states earlier during disease onset, while also enabling more targeted and effective treatment regimens. The Multilisa SSc program includes the first of a number of new CE-approved IVD tests, Multilisa BICD2, CENP-B and Scl-70, in the pipeline. Protagen also has a number of other test programs on the horizon including Multilisa RA and SLE.
Autoimmune Patient Stratification
The ability to stratify patients into different disease subgroups based on the individual molecular characteristics of each subtype can drive better drug development and improve the success rate of clinical trials. To this end, Protagen’s NavigAID companion diagnostic concept has been designed to better stratify patients suffering with autoimmune diseases. NavigAID SLE the first to be made available so far. The NavigAID stratification tool enables differential diagnosis, better disease activity assessment and improved response prediction. Protagen has a number of other NavigAID products in the pipeline including NavigAID SSc, RA and SjS.